The National Institutes of Health's National Institute of Child Health and Human Development awarded a multiple award indefinite delivery contract to the University of Hawaii at Manoa to support the agency's Contraceptive Development Program and Contraceptive Clinical Trials Network. The contract has a potential value of $5 million and period of performance through July 2027.
Two delivery orders have been awarded against the contract to date. The first is a $64k order for protocol finalization and start-up activities to commence a Phase 1 clinical trial of the OVAPRENE vaginal device in Honolulu through September 2024. The second is a $114k order for protocol review, development, and associated activities in support of past, present and future efforts under the Contraceptive Clinical Trials Network in Honolulu through July 2027. No set-asides were used for these awards.
The original solicitation sought a contractor to perform Phase I-IV clinical trials of new and existing female contraceptive methods to support the development of safe and effective products within the National Institutes of Health's research programs focused on maternal and child health. The University of Hawaii at Manoa will serve as the prime contractor, utilizing its clinical trial expertise and local facilities.
Generated 1/5/24, 2:12 AM